PACAP

Drug Profile

PACAP

Alternative Names: PACAP 1-27; PACAP 1-38; PACAP 6-38; PACAP-27; PACAP-38; Pituitary adenylate cyclase activating polypeptide

Latest Information Update: 19 Sep 2003

Price : $50

At a glance

  • Originator Tulane University
  • Class Muscle relaxants; Neuropeptides; Peptides; Vasodilators
  • Mechanism of Action Adenylate cyclase inhibitors; Adenylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Neurological disorders; Non-small cell lung cancer; Stroke

Most Recent Events

  • 19 Sep 2003 Discontinued - Phase-I for Stroke in Europe (unspecified route)
  • 19 Sep 2003 Discontinued - Phase-I for Neurological disorders in Europe (unspecified route)
  • 19 Sep 2003 Discontinued - Phase-I for Asthma in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top